Boyer discusses a potential treatment for diabetic retinopathy and macular degeneration using suprachoroidal injections, ...

The TEASE-1 trial reveals gildeuretinol's potential to reduce vision loss in Stargardt disease, offering hope for future ...

The ranibizumab ocular implant (Susvimo) reduces the need for frequent intravitreal anti-VEGF injections in patients with neovascular age-related macular degeneration or diabetic macular edema, and ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

Retinitis Pigmentosa therapies evolve beyond gene-specific fixes with gene-agnostic, intravitreal, and optogenetic advances ...

W. L. Gore & Associates, Inc. ("Gore"), a global materials science company, recently announced the commercial launch of the 0 ...

The new offering, designed specifically for prefilled syringes used in various applications, complements its 1 mL ImProject ...

One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months ...